Copyright
©The Author(s) 2020.
World J Gastroenterol. Aug 14, 2020; 26(30): 4465-4478
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4465
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4465
Figure 3 Lenvatinib-related adverse events in patients with hepatocellular carcinoma.
The brown bar represents grade 3-4 adverse events; the blue bar represents all-grade adverse events.
- Citation: Wang DX, Yang X, Lin JZ, Bai Y, Long JY, Yang XB, Seery S, Zhao HT. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China. World J Gastroenterol 2020; 26(30): 4465-4478
- URL: https://www.wjgnet.com/1007-9327/full/v26/i30/4465.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i30.4465